AlphAIAlphAI — Financial news for AI agents
minichart.com.sgOCT 302 min read$KVUE

Kenvue Q3 2026: Sales Up 3.2% to $3.89B, Adjusted EPS $0.29, No Guidance on Kimberly-Clark Deal

Kenvue Inc. (NYSE: KVUE) reported Q3 2026 net sales of $3.89B, up 3.2% YoY, with adjusted EPS of $0.29. Gross and operating margins improved, driven by supply-chain savings and tariff refunds. Self Care and Essential Health segments grew, while Skin Health and Beauty lagged. Free cash flow rose to $1.6B. No guidance was provided due to the pending Kimberly-Clark deal.

Original reporting
minichart.com.sg
Published Oct 30, 2026, 2:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 3:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Kenvue Q3 2026: Sales Up 3.2% to $3.89B, Adjusted EPS $0.29, No Guidance on Kimberly-Clark Deal — source image
Source · minichart.com.sg
Decision brief

The 30-second read

$KVUENeutralMed
01

Why it matters

The earnings release provides fresh data on sales growth, margin improvement, and cash generation, while the lack of guidance adds volatility risk.

02

Market read

Kenvue's earnings and merger uncertainty are likely to move the stock and influence the broader consumer staples sector.

03

What to watch

The modest margin expansion and strong free cash flow suggest underlying operational strength that could support the stock if investors focus on fundamentals.

Relevance 8/10Novelty 8/10Timing: today

Background

Kenvue is a spin‑off of Kimberly‑Clark's consumer health business; the pending transaction creates a unique earnings environment.

Company-level read

Ticker impact

$KVUENeutralHigh confidence
Context

Kenvue reported Q3 2026 earnings with sales up 3.2% to $3.89B and adjusted EPS $0.29, but gave no forward guidance due to the pending Kimberly-Clark deal.

Expected impact

potential pressure as investors price in merger uncertainty and missing guidance

Evidence & confidence

The numbers are fresh and material, yet the absence of guidance and merger risk may weigh on the stock in the near term.

Market effects

Sector

Consumer health and personal care sector may see heightened scrutiny of merger activity.

Regional

U.S. consumer staples investors may adjust exposure pending deal outcome.

Global

The Kimberly-Clark combination could affect global supply chains in the hygiene products market.

Counterpoint

What could challenge this read

If the merger proceeds smoothly, the combined entity could unlock synergies and drive upside despite short‑term uncertainty.

Key entities

  • company
    Kenvue Inc.

    Consumer health and personal care products company reporting Q3 2026 results.

  • company
    Kimberly-Clark

    Potential acquirer; pending merger influences Kenvue's guidance and investor sentiment.

Read at source← All news

StoryKenvue posts Q3 2026 earnings amid pending Kimberly‑Clark merger

Also covered by

5 outlets

Related articles

OCT 30
$OKTAHighAI 8/10

Okta to Replace Kenvue in S&P 500 Amid Kimberly-Clark Acquisition

S&P Dow Jones Indices announced Okta (OKTA) will replace Kenvue (KVUE) in the S&P 500 on November 4, 2026, due to Kenvue's acquisition by Kimberly-Clark (KMB). Kenvue's valuation is $48.7B, with a $21.01 per-share consideration. Glaukos (GKOS) will replace Okta in the S&P MidCap 400, and McGrath RentCorp (MGRC) will replace Glaukos in the S&P SmallCap 600. Loar Holdings (LOAR) will replace LiveRamp (RAMP) in the S&P SmallCap 600 due to LiveRamp's acquisition by Publicis Groupe (PU4.DE).

securities.io3 min
OCT 30
$KVUEHighAI 8/10

Kenvue posts higher profit, fourth straight sales gain in Q3 earnings

Kenvue reported Q3 adjusted earnings per share of 29 cents, up from 28 cents, and organic sales growth of 2.9%. Revenue exceeded $3.86 billion, matching analyst estimates. Self Care net sales rose 5.9%, while Skin Health and Beauty saw a slight decline. Gross and operating margins improved, and free cash flow increased. CEO Kirk Perry noted progress in operational overhaul and the pending combination with Kimberly-Clark.

qz.com2 min
OCT 30
$KVUEMed

Kenvue Delivers Fourth Consecutive Quarter of Sales Growth

Kenvue reported Q3 2026 net sales growth of 3.2% and organic sales growth of 2.9%, marking four consecutive quarters of sales growth. CEO Kirk Perry attributed the performance to strong execution, productivity initiatives, and brand investments. Skin Health & Beauty sales declined slightly, while Hair Care saw double-digit growth. Self Care segment increased by 5.9%. The company is on track for its business transformation and upcoming combination with Kimberly-Clark.

beautypackaging.com2 min
OCT 30
$KVUEHighAI 9/10

Kenvue Q3 Sales Rise 3.2% as EPS Increases 5%

Kenvue reported Q3 2026 net sales growth of 3.2% to $4.1B, with EPS up 5% to $0.22. Organic sales rose 2.9%, driven by volume growth and value realization. Gross and operating margins improved, while cash flow increased. The company did not provide guidance due to its pending merger with Kimberly-Clark.

grafa.com2 min
OCT 30
$KVUEMed

Kenvue 3Q 2026: Revenue $3.89B, EPS $0.22— 10-Q Summary

Kenvue reported Q3 2026 net sales of $3.89B, up 3.2% YoY, with net income increasing 8% to $430M and EPS rising 4.8% to $0.22. Organic sales grew 2.9% in the quarter, with Self Care sales up 5.9% and Essential Health up 2.5%. The company aims for $200M in annual savings and is divesting feminine-care businesses as part of merger regulatory steps.

tradingview.com1 min